<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539655</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00101</org_study_id>
    <nct_id>NCT01539655</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib</brief_title>
  <acronym>Vandetanib</acronym>
  <official_title>A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study in healthy volunteers to assess effect of omeprazole and ranitidine on the
      pharmacokinetics of vandetanib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of
      Vandetanib (CAPRELSA) in Healthy Subjects when a Single Oral Dose of Vandetanib 300 mg is
      Administered Alone and in Combination with Omeprazole or Ranitidine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for a single dose of vandetanib alone and in combination with omeprazole (PPI)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for a single dose of vandetanib alone and in combination with omeprazole (PPI)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for a single dose of vandetanib alone and in combination with ranitidine (histamine antagonist)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for a single dose of vandetanib alone and in combination with ranitidine (histamine antagonist)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters for a single dose of vandetanib alone and in combination with omeprazole (PPI)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters for a single dose of vandetanib alone and in combination with ranitidine (histamine antagonist)</measure>
    <time_frame>Predose,1,2,3,4,5,6,7,8,10,12,18,24,36,48,72,96,120,144,168,192,216,240,336,504 ,672 hrs post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>vandetanib then vandetanib + omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vandetanib + omeprazole then vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vandetanib then vandetanib + ranitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vandetanib + ranitidine then vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vandetanib</intervention_name>
    <description>Oral tablets, 300 mg, single dose</description>
    <arm_group_label>vandetanib then vandetanib + omeprazole</arm_group_label>
    <arm_group_label>vandetanib + omeprazole then vandetanib</arm_group_label>
    <arm_group_label>vandetanib then vandetanib + ranitidine</arm_group_label>
    <arm_group_label>vandetanib + ranitidine then vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>Oral capsules, 40 mg, multiple doses</description>
    <arm_group_label>vandetanib then vandetanib + omeprazole</arm_group_label>
    <arm_group_label>vandetanib + omeprazole then vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranitidine</intervention_name>
    <description>Oral tables, 150 mg, multiple doses</description>
    <arm_group_label>vandetanib then vandetanib + ranitidine</arm_group_label>
    <arm_group_label>vandetanib + ranitidine then vandetanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study-specific
             procedures

          -  Volunteers must be males or females aged 18 to 50 years and with a weight of at least
             50 kg and body mass index (BMI) between 18 and 30 kg/m2

          -  Inclusive Females must have a negative pregnancy test at screening and on admission to
             the study center

          -  Females must not be lactating and must be of non childbearing potential defined as
             postmenopausal or documentation of irreversible surgical sterilization.

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder such as gastrointestinal,
             hepatic, renal or skin disease.

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity

          -  Volunteers who smoke more than 5 cigarettes per day or are unable to refrain from
             smoking while resident in the study center

          -  Screening blood pressure of greater than 140/90 mmHg and/or a resting heart rate of
             less than 45 beats per minute (repeat test allowed at the Investigator's discretion

          -  Clinically significant abnormal12-lead ECG as assessed by the Investigator

          -  QTcF interval greater than 450 ms Any positive result on screening for serum hepatitis
             B surface antigen, hepatitis C antibody

          -  Human immunodeficiency virus (HIV), or positive screen for drugs of abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1436&amp;filename=CSR-D4200C00101.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1436&amp;filename=CSR-D4200C00101.pdf</url>
    <description>CSR-D4200C00101.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1436&amp;filename=D4200C00101_Revised_CSP_redacted.pdf</url>
    <description>Revised_CSP_redacted</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>vandetanib</keyword>
  <keyword>omeprazole</keyword>
  <keyword>ranitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

